Daniel Schneider - Photocure President CEO

PHO Stock  NOK 50.50  2.10  4.34%   

CEO

Mr. Daniel Schneider was appointed President and Chief Executive Officer of PHOTOCURE ASA effective as of prior to November 1, 2018. Mr. Schneider holds an MBA from Washington University and a BS degree in Business Administration from St. Louis University with a double major in Finance and Marketing. Mr. Schneider has commercial experience from the U.S. healthcare industry, including his previous position as General Manager for Ablynx N.V. in North America. Mr. Schneider has also held executive management positions in other pharmaceutical and biotech companies, including BTG International, Somaxon Pharmaceuticals and Sepracor. since 2018.
Tenure 6 years
Phone(47) 22 06 22 18
Webwww.photocure.no

Photocure Management Efficiency

The company has return on total asset (ROA) of (0.0309) % which means that it has lost $0.0309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1567) %, meaning that it generated substantial loss on money invested by shareholders. Photocure's management efficiency ratios could be used to measure how well Photocure manages its routine affairs as well as how well it operates its assets and liabilities.
Photocure has accumulated 12.5 M in total debt with debt to equity ratio (D/E) of 5.5, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Photocure has a current ratio of 2.98, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Photocure until it has trouble settling it off, either with new capital or with free cash flow. So, Photocure's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Photocure sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Photocure to invest in growth at high rates of return. When we think about Photocure's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 8 records

CEO Age

PetterBorre FurbergTelenor ASA
56
Lasse KvinlaugSparebanken Sor
62
Eldar SaetreEquinor ASA
63
Jukka LeinonenTelenor ASA
57
Albern MurtyTelenor ASA
47
JanFrode JansonSparebank 1 SMN
54
Petter FurbergTelenor ASA
52
Irfan KhanTelenor ASA
N/A
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products and related technical medical equipment in Nordic countries and the United States. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway. PHOTOCURE ASA operates under Drug Manufacturers - Major classification in Norway and is traded on Oslo Stock Exchange. It employs 71 people. Photocure (PHO) is traded on Oslo Stock Exchange in Norway and employs 97 people.

Management Performance

Photocure Leadership Team

Elected by the shareholders, the Photocure's board of directors comprises two types of representatives: Photocure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Photocure. The board's role is to monitor Photocure's management team and ensure that shareholders' interests are well served. Photocure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Photocure's outside directors are responsible for providing unbiased perspectives on the board's policies.
Tolv Hillestad, Group Controller
Erik Dahl, Chief Officer
Patricia Kelly, VP HR
David Moskowitz, Head Relations
Daniel Schneider, President CEO
Anders Neijber, Clinical Affairs
Kari MD, Head Devel
Geoffrey Coy, VP Operations

Photocure Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Photocure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Photocure Stock

Photocure financial ratios help investors to determine whether Photocure Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Photocure with respect to the benefits of owning Photocure security.